News | July 21, 2021
Syngene Q1 FY22 revenue grows 41%
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
Vikas Lifecare has already paid Rs. 25 million to the Advik bankers till date and the remaining amount shall also be paid within July 2021, making Advik a debt free company
Sun Pharma has committed Rs. 100 crores towards these initiatives
ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials
2-DG was developed by the Institute of Nuclear Medicine & Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy's
Bayer Zydus Pharma will continue to operate in core therapies with new products in the pipeline
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
India is expecting to manufacture 30-35 crore COVID-19 vaccines between July - August 2021
The company has launched Perampil, at 2 mg (Rs. 49/strip of 7 tablets), 4 mg (Rs. 180/strip of 15 tablets) and 6 mg (Rs. 300/strip of 15 tablets) to improve patient access
The agreements between the parties involve a total fee of Rs. 8 lakh plus taxes for the grant of the licenses on a non-exclusive basis to SPL
Subscribe To Our Newsletter & Stay Updated
